JP2023526500A5 - - Google Patents

Info

Publication number
JP2023526500A5
JP2023526500A5 JP2022571167A JP2022571167A JP2023526500A5 JP 2023526500 A5 JP2023526500 A5 JP 2023526500A5 JP 2022571167 A JP2022571167 A JP 2022571167A JP 2022571167 A JP2022571167 A JP 2022571167A JP 2023526500 A5 JP2023526500 A5 JP 2023526500A5
Authority
JP
Japan
Prior art keywords
seq
peptide
composition according
immunotherapy composition
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022571167A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023526500A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/033222 external-priority patent/WO2021236809A2/en
Publication of JP2023526500A publication Critical patent/JP2023526500A/ja
Publication of JP2023526500A5 publication Critical patent/JP2023526500A5/ja
Pending legal-status Critical Current

Links

JP2022571167A 2020-05-19 2021-05-19 アルツハイマー病の処置のためのマルチエピトープワクチン Pending JP2023526500A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063027150P 2020-05-19 2020-05-19
US63/027,150 2020-05-19
US202063062903P 2020-08-07 2020-08-07
US63/062,903 2020-08-07
US202163140917P 2021-01-24 2021-01-24
US63/140,917 2021-01-24
PCT/US2021/033222 WO2021236809A2 (en) 2020-05-19 2021-05-19 Multi-epitope vaccine for the treatment of alzheimer's disease

Publications (2)

Publication Number Publication Date
JP2023526500A JP2023526500A (ja) 2023-06-21
JP2023526500A5 true JP2023526500A5 (enExample) 2024-05-28

Family

ID=78708070

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022571167A Pending JP2023526500A (ja) 2020-05-19 2021-05-19 アルツハイマー病の処置のためのマルチエピトープワクチン

Country Status (15)

Country Link
US (6) US20230183304A1 (enExample)
EP (1) EP4153210A4 (enExample)
JP (1) JP2023526500A (enExample)
KR (1) KR20230037501A (enExample)
CN (1) CN115867304A (enExample)
AU (1) AU2021276401A1 (enExample)
BR (1) BR112022023366A2 (enExample)
CA (1) CA3178760A1 (enExample)
CL (2) CL2022003253A1 (enExample)
IL (1) IL298215A (enExample)
JO (1) JOP20220316A1 (enExample)
MX (1) MX2022014453A (enExample)
PH (1) PH12022553234A1 (enExample)
TW (1) TW202208409A (enExample)
WO (1) WO2021236809A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7490575B2 (en) 2005-11-08 2009-02-17 Temptime Corporation Combination freeze indicators
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
US20230364210A1 (en) * 2020-09-17 2023-11-16 Othair Prothena Limited ß-AMYLOID VACCINE FOR THE TREATMENT OF ALZHEIMER’S DISEASE
CN116438191A (zh) * 2020-09-18 2023-07-14 欧萨尔普罗席纳有限公司 治疗阿尔茨海默病之多表位疫苗
CN116554342A (zh) * 2022-01-29 2023-08-08 元本(珠海横琴)生物科技有限公司 一种融合表达Tau-4R蛋白的大肠杆菌工程菌株
JP2025507875A (ja) 2022-02-28 2025-03-21 トライデム バイオサイエンス ゲーエムベーハー ウント コンパニー カーゲー 少なくともβ－グルカン若しくはマンナンからなるか、又はこれを含む結合体
EP4486389A1 (en) 2022-02-28 2025-01-08 Tridem Bioscience GmbH & Co KG A conjugate comprising at least a beta-glucan
CU20230023A7 (es) 2023-05-12 2024-12-09 Ct Ingenieria Genetica Biotecnologia Antígeno quimérico multiblanco para la inmunoterapia de la enfermedad de alzheimer
CN120919292A (zh) * 2025-08-04 2025-11-11 首都医科大学宣武医院 用于预防或治疗阿尔茨海默病的Aβ-Tau多表位疫苗及其用途

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208036A (en) 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5674703A (en) 1992-12-02 1997-10-07 Woo; Savio L. C. Episomal vector systems and related methods
DE69435171D1 (de) 1993-09-14 2009-01-08 Pharmexa Inc Pan dr-bindeproteinen zur erhöhung der immunantwort
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
US5840838A (en) 1996-02-29 1998-11-24 University Of Kentucky Research Foundation Process for enhancing the activity of amyloid β peptides
DK1005368T3 (da) 1997-03-10 2010-01-04 Ottawa Hospital Res Inst Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
US7632816B2 (en) * 2003-03-28 2009-12-15 New York University Treatment of Alzheimer amyloid deposition
WO2007011907A2 (en) 2005-07-19 2007-01-25 University Of Rochester Alpha-synuclein antibodies and methods related thereto
WO2007103770A2 (en) * 2006-03-02 2007-09-13 Ppd Biomarker Discovery Sciences, Llc Compositions and methods for analyzing renal cancer
WO2008081008A1 (en) 2007-01-05 2008-07-10 University Of Zurich Method of providing disease-specific binding molecules and targets
US8377875B2 (en) * 2007-01-11 2013-02-19 Ramot At Tel-Aviv University Ltd. Therapeutics based on tau/microtubule dynamics
AT506819B1 (de) 2008-06-12 2011-06-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzin zur behandlung von alzheimer-krankheit
CN106390107B (zh) * 2009-06-10 2019-12-31 纽约大学 病理tau蛋白的免疫靶向
EP2382993A1 (en) * 2010-04-19 2011-11-02 KTB Tumorforschungsgesellschaft mbH Combination of drugs with protein-binding prodrugs
ME03008B (me) * 2011-09-19 2018-10-20 Axon Neuroscience Se Terapija na osnovu proteina i dijagnoza patologije u којој posreduje tau u alcнajмerovoj bolesti
US9738709B2 (en) * 2011-10-21 2017-08-22 Ohio State Innovation Foundation Methylated peptides derived from tau protein and their antibodies for diagnosis and therapy of alzheimer's disease
EP2887955B1 (en) * 2012-08-21 2020-08-19 Institute for Molecular Medicine, Inc. Compositions and methods related to diseases associated with deposits of amyloid, tau, and alpha-synuclein
US20170368167A9 (en) * 2012-08-21 2017-12-28 The Institute For Molecular Medicine Compositions and methods related to neurological disorders
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US10501531B2 (en) 2013-03-13 2019-12-10 Prothena Biosciences Limited Tau immunotherapy
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
CN108778289B (zh) 2015-11-06 2020-11-17 佐剂技术公司 三萜皂苷类似物
MX2018013386A (es) 2016-05-02 2019-02-28 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
PT3452507T (pt) 2016-05-02 2022-12-20 Prothena Biosciences Ltd Imunoterapia anti-tau
MY198194A (en) 2016-05-02 2023-08-09 Prothena Biosciences Ltd Antibodies Recognizing Tau
CA3051839A1 (en) 2017-02-17 2018-08-23 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
WO2018191598A1 (en) 2017-04-13 2018-10-18 Adjuvance Technologies, Inc. Triterpene saponin synthesis, intermediates and adjuvant combinations
US20200164065A1 (en) 2017-04-25 2020-05-28 Adjuvance Technologies, Inc. Triterpene saponin analogues
KR102784294B1 (ko) 2017-05-02 2025-03-19 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
EP3638298A4 (en) 2017-06-16 2021-05-05 United Neuroscience PEPTIDE IMMUNOGENS FROM THE C-TERMINAL END OF ALPHA-SYNUCLEIN-PROTEIN AND FORMULATIONS THEREOF FOR THE TREATMENT OF SYNUCLEINOPATHIA
WO2019070480A1 (en) 2017-10-02 2019-04-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services ASSAY FOR DETECTION OF ALPHA-SYNUCLEIN SELF-ACTIVATION ACTIVITY ASSOCIATED WITH SYNUCLEINOPATHIES
WO2019070813A2 (en) * 2017-10-03 2019-04-11 The Trustees Of Columbia University In The City Of New York USE OF PEPTIDES AS BIOMARKERS IN THE DIAGNOSIS, CONFIRMATION AND TREATMENT OF A NEUROLOGICAL DISORDER
SG11202001826YA (en) 2017-10-16 2020-03-30 Adjuvance Technologies Inc Triterpene saponin analogues
WO2022032166A1 (en) * 2020-08-07 2022-02-10 Othair Prothena Limited Multiepitope vaccine for the treatment of alzheimer's disease

Similar Documents

Publication Publication Date Title
JP2023526500A5 (enExample)
JP2023541670A5 (enExample)
JP2023541669A5 (enExample)
JP2023536995A5 (enExample)
Barr et al. ISCOMs (immunostimulating complexes): the first decade
TWI355390B (en) Immunogenic peptide carrier conjugates and methods
JP2023536746A5 (enExample)
CA2167730A1 (en) Synthetic multiple tandem repeat mucin and mucin-like peptides and uses thereof
JP2023541671A5 (enExample)
JP2012523379A (ja) 免疫原性組成物およびその使用
TW202212348A (zh) 用於治療阿茲海默症之β類澱粉蛋白疫苗
US20030175285A1 (en) Molecule of pharmaceutical interest comprising at its n-terminal a glutamic acid or a glutamine in the form of a physiologically acceptable strong acid
JP2023541670A (ja) アルツハイマー病の処置のためのマルチエピトープワクチン
JP6352251B2 (ja) Ｃｒｍ１９７担体タンパク質に結合したｈｉｖｇｐ４１ペプチドを含む免疫原性化合物
US20050049197A1 (en) Induction of immune response against desired determinants
US20220362159A1 (en) Tabletization of peptide self-assemblies and methods of making and using the same
TW202221022A (zh) 用於治療阿茲海默症之ｔａｕ疫苗
KR20220062080A (ko) 전립선암 치료를 위한 면역요법
CN116783211A (zh) 治疗突触核蛋白病之α-突触核蛋白疫苗
Goodman-Snitkoff et al. Role of intrastructural/intermolecular help in immunization with peptide-phospholipid complexes
CN116261464A (zh) 免疫原性化合物
Verheul et al. Monopalmitic acid-peptide conjugates induce cytotoxic T cell responses against malarial epitopes: importance of spacer amino acids
US20100266623A1 (en) Synthetic, self adjuvanting vaccines
US20110262473A1 (en) Synthetic vaccine component
ES2908071T3 (es) Composición de vacuna y usos de la misma